Choose diuretics by nephron site, volume status, and treatment goal. Connect electrolyte effects to safe prescribing and interpret newer trial evidence.
Two patients have swollen legs. One has pulmonary congestion and needs prompt sodium excretion. The other has cirrhosis, falling blood pressure, and new kidney injury. Giving both a larger loop dose because both look edematous misses the decision that matters. Identify the treatment goal and effective circulation before choosing where to interrupt tubular transport.
Follow the filtrate, then predict what reaches the collecting duct
A diuretic changes a transport process, not just urine volume. Most filtered sodium is reclaimed before the distal nephron. Blocking a large upstream transport capacity produces substantial natriuresis, but downstream segments reclaim some of the delivered sodium. Greater distal sodium delivery, tubular flow, and aldosterone activity explain much of the potassium loss from loop and thiazide therapy. Drug delivery into the tubular lumen also matters. A swallowed dose is not equivalent to a known concentration at its target.
Filtrate travels through these sites in order. Each entry connects a luminal target to its downstream consequence.
Proximal tubule
Acetazolamide inhibits carbonic anhydrase and reduces bicarbonate reclamation. More sodium bicarbonate reaches later segments.
Water-permeable proximal and descending segments
Filtered mannitol retains water osmotically within tubular fluid.
Thick ascending limb
Loop drugs inhibit apical NKCC2. Sodium chloride excretion increases and the medullary concentrating gradient weakens.
Early distal convoluted tubule
Thiazide drugs inhibit NCC. This cortical diluting segment normally absorbs salt without accompanying water.
Late distal nephron and collecting duct
Amiloride and triamterene inhibit ENaC. Spironolactone and eplerenone antagonize the mineralocorticoid receptor. Both approaches reduce potassium secretion through separate potassium channels.
Collecting duct water pathway
Vasopressin antagonists reduce hormone-dependent water permeability. Their principal effect is aquaresis rather than strong sodium excretion.
Use approximate sodium fractions as orientation, not a ranking of clinical usefulness. The thick ascending limb handles about one quarter of the filtered sodium load, while the early distal tubule handles roughly five percent. A drug with modest natriuresis can still have a valuable disease-specific effect. Mineralocorticoid receptor antagonists improve outcomes in selected heart failure patients, and amiloride directly addresses ENaC overactivity in Liddle syndrome. [5][15]
Try it here · Checkpoint 1 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 2
Show answer and explanations for case 2
A. Increased calcitriol-mediated calcium absorption at calcium-handling sites (Why this does not fit)
Calcitriol mainly increases intestinal calcium absorption; it does not explain the direct TAL voltage effect after furosemide.
B. Loss of the TAL lumen-positive voltage needed for paracellular calcium absorption (Best answer)
NKCC2 inhibition disrupts potassium recycling and its associated voltage, reducing calcium absorption between tubular cells.
C. Stimulation of distal sodium-calcium exchange that markedly increases calcium reabsorption (Why this does not fit)
Greater distal calcium absorption would favor calcium retention rather than the urinary calcium increase described.
D. Increased proximal bicarbonate reclamation with preserved calcium handling (Why this does not fit)
Proximal bicarbonate transport is not the loop target and does not account for the characteristic loss of TAL calcium absorption.
Takeaway: Loop calcium loss follows a change in TAL voltage.
Separate sodium excretion from calcium and water effects
The loop has a calcium consequence
Furosemide, bumetanide, torsemide, and ethacrynic acid interrupt NKCC2 in the thick ascending limb. Potassium recycling into the lumen normally helps establish a positive luminal voltage that supports paracellular calcium and magnesium absorption. Loop inhibition reduces that voltage, increasing calcium and magnesium losses. Increased distal sodium delivery and secondary aldosterone activity favor hypokalemia and metabolic alkalosis. Chloride depletion, reduced effective circulation, and potassium depletion can maintain the alkalosis after the initial diuresis. Check blood pressure, congestion, creatinine, sodium, potassium, magnesium, and bicarbonate as the clinical situation requires. [1]
The ear contains a related transporter, NKCC1, on the basolateral side of strial marginal cells. It contributes to potassium uptake into those cells and thereby supports potassium-rich endolymph. It is not the renal NKCC2 transporter and does not itself secrete potassium across the apical membrane into endolymph. This distinction explains an off-target effect without inventing a shared anatomical location. Loop-associated hearing injury is more likely with rapid administration, high doses, renal impairment, hypoproteinemia, and other ototoxic drugs such as aminoglycosides. Injury can be reversible or persistent. Follow the product-specific administration instructions. [1][20]
The thiazide has a dilution consequence
Hydrochlorothiazide, chlorthalidone, and metolazone inhibit NCC. They impair urinary dilution while leaving the medullary concentrating system relatively available. Water intake and antidiuresis can therefore produce profound hyponatremia, particularly after treatment initiation in susceptible patients. A thiazide is not a strategy to prevent hyponatremia in an older adult. Loops generally pose less risk through this particular mechanism, but any diuretic can contribute to electrolyte abnormalities and volume depletion. Thiazides can also cause potassium and magnesium depletion, hyperuricemia, gout, and dose-related metabolic adverse effects. [7][21]
Loop pattern Increased urinary calcium and magnesium, reduced concentrating ability, possible hypokalemic alkalosis.
Thiazide pattern Reduced urinary calcium, impaired dilution, possible hyponatremia and hypokalemic alkalosis.
Thiazide-associated calcium retention is not explained solely by a distal sodium-calcium exchanger diagram. Volume-related enhancement of proximal calcium reabsorption contributes substantially in experimental work. Less urinary calcium does not establish that every recurrent stone patient will benefit clinically. In NOSTONE, hydrochlorothiazide did not significantly reduce the primary composite recurrence outcome compared with placebo across the studied doses. Discuss fluid intake, dietary sodium, urine chemistry, recurrence burden, and adverse effects when considering medication for selected patients with hypercalciuria. Persistent hypercalcemia warrants evaluation, including for primary hyperparathyroidism. [9][17]
Two older prescribing shortcuts also fail. CLICK demonstrated blood pressure lowering with chlorthalidone in stage 4 CKD, so an eGFR below 30 mL/min/1.73 m² does not make all thiazide-like therapy ineffective. The Diuretic Comparison Project enrolled VA patients aged at least 65 years who were already receiving hydrochlorothiazide 25 or 50 mg daily. In that population, it did not establish cardiovascular superiority of chlorthalidone over hydrochlorothiazide and found more hypokalemia with chlorthalidone. Choose with attention to duration, kidney function, prior response, and monitoring rather than a universal winner. [7][8]
Use the smaller transport targets for a specific purpose
Acetazolamide reduces proximal bicarbonate reclamation, causing bicarbonaturia, initially alkaline urine, and a hyperchloremic metabolic acidosis. Potassium can fall. Calcium phosphate stones become more likely in alkaline urine. The same carbonic anhydrase target supports uses in glaucoma, idiopathic intracranial hypertension, and altitude illness prevention. Reduced aqueous humor production helps lower intraocular pressure; reduced cerebrospinal fluid production is relevant to intracranial pressure.
IIHTT supports selected acetazolamide use alongside weight management in IIH with mild visual loss. [25] At altitude, bicarbonate loss promotes ventilation by offsetting respiratory alkalosis. Avoid acetazolamide in cirrhosis because it can increase encephalopathy risk, and observe label restrictions in marked kidney dysfunction and preexisting electrolyte or acid-base depletion. [2][19]
Acetazolamide also has a contemporary inpatient congestion role. ADVOR found more successful early decongestion when intravenous acetazolamide was added to loop therapy in selected adults with acute decompensated heart failure and volume overload. The trial added acetazolamide early to a standardized IV loop regimen in patients with objective congestion, elevated natriuretic peptides, and prior maintenance loop therapy. It excluded eGFR below 20 mL/min/1.73 m², systolic pressure below 90 mmHg, and SGLT2 inhibitor treatment. It did not establish a mortality advantage or test every form of rescue therapy after prolonged loop resistance. [10]
Mannitol is filtered and retains water in the lumen. Before excretion, its osmotic effect can expand the vascular compartment and worsen pulmonary congestion. Its established uses include selected intracranial and intraocular pressure indications. Anuria, severe hypovolemia, and preexisting severe pulmonary vascular congestion or pulmonary edema are important contraindications. Monitor kidney function, volume, electrolytes, and osmotic exposure. Routine forced diuresis for an unspecified overdose or attempted reversal of established anuric kidney failure is not an appropriate default indication. [3]
Spironolactone and eplerenone reduce aldosterone-mediated sodium retention and potassium excretion. Eplerenone is more selective and generally has fewer sex-hormone adverse effects; spironolactone can cause breast tenderness and gynecomastia. Both can cause hyperkalemia. For guideline-directed initiation in symptomatic HFrEF, the usual eligibility includes eGFR above 30 mL/min/1.73 m² and potassium below 5.0 mmol/L, followed by close laboratory surveillance. Spironolactone labeling calls for potassium assessment within one week of initiation or titration. The outcome benefit does not mean these agents lack diuretic or blood pressure effects. [6][15]
Amiloride and triamterene block ENaC directly. This is why amiloride is useful in Liddle syndrome even when aldosterone is suppressed. [23] Amiloride also limits lithium entry into principal cells and can improve lithium-associated nephrogenic diabetes insipidus under supervised management. It does not make continued lithium exposure automatically safe. Review lithium concentration, kidney function, interacting medicines, and the psychiatric treatment plan. Combining potassium-sparing drugs with RAAS inhibitors or potassium supplements increases hyperkalemia risk. [5][18]
Thiazides can paradoxically reduce polyuria in selected nephrogenic diabetes insipidus patients. Their antidiuretic effect is used with a suitable low-solute diet and reliable water access; electrolyte and volume monitoring remain necessary. This is a different indication from correcting a low serum sodium. In lithium-treated patients, thiazides can increase lithium exposure, so medication selection and lithium monitoring require particular care. [28][18]
Try it here · Checkpoint 2 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 11
Show answer and explanations for case 11
A. Choose acetazolamide primarily to reduce postdischarge mortality (Why this does not fit)
The trial established an early decongestion benefit, not a mortality advantage.
B. Replace the IV loop with acetazolamide monotherapy (Why this does not fit)
ADVOR tested acetazolamide added to standardized loop treatment, not a replacement regimen.
C. Adjunctive IV acetazolamide to improve early decongestion in a suitable patient (Best answer)
ADVOR supports this selected inpatient strategy; renal status and electrolytes still determine safe application.
D. Add oral acetazolamide only after several weeks of loop resistance (Why this does not fit)
That timing and route differ from the early inpatient IV adjunct evaluated in ADVOR.
Takeaway: An additional nephron target can improve a specific outcome without proving every other benefit.
Explain a weak response before adding another drug
A patient can remain congested because the dose never reaches an effective luminal concentration, because sodium intake replaces the excreted load, or because later nephron segments compensate. Check adherence, administered dose, absorption during gut edema, kidney function, urine output, perfusion, urinary obstruction, and interacting NSAIDs. Loop drugs require proximal tubular secretion to access their luminal target. CKD can reduce effective delivery, making higher doses necessary, but an eGFR alone cannot prescribe an exact dose.
Intravenous dosing bypasses uncertain gastrointestinal absorption. Oral furosemide has variable bioavailability; common conversion approximations are starting tools, not exact equivalence for every patient. Reassess urine response and symptoms after the selected dose. The DOSE trial did not establish continuous infusion as universally superior to intermittent boluses on its primary symptom and creatinine outcomes. TRANSFORM-HF, published in 2023, did not demonstrate lower mortality with torsemide than furosemide after a heart failure hospitalization. [1][11][12]
When a suitable loop regimen remains inadequate, adding a thiazide-like agent such as metolazone can reduce compensatory distal sodium reabsorption. This combination can also sharply lower sodium and potassium and worsen kidney function. Its physiological rationale does not establish a mandatory thirty-minute interval between drugs. Selected inpatient patients may instead benefit from proximal blockade with acetazolamide. Choose the additional target using congestion, bicarbonate, electrolytes, renal function, and the evidence relevant to that patient. [10][15]
Low serum albumin is one contributor to complicated edema and drug distribution, not proof that albumin infusion will correct diuretic resistance. KDIGO allows consideration of albumin with IV diuretics in selected patients with nephrotic edema resistant to adequate IV diuretic therapy, especially with marked hypoalbuminemia; benefit can be transient and the evidence is limited. [26] Assess intravascular filling and the cause of nephrotic or hepatic edema.
In cirrhosis, a spironolactone-to-furosemide regimen around 100 mg to 40 mg is a familiar starting framework when combination treatment is appropriate, not a guarantee of potassium balance. During ascites treatment, follow daily weight: generally avoid loss exceeding 0.5 kg/day without peripheral edema or 1 kg/day when peripheral edema is present. These are safety limits rather than mandatory daily targets.
New hypotension, marked creatinine increase, hyponatremia, or hyperkalemia requires reassessment and often holding diuretics while investigating the complication. Do not add metolazone reflexively to a patient developing AKI. [16]
Early vascular responses to IV furosemide have been measured before substantial fluid loss. A small human study found increased venous capacitance under some conditions, with the response inhibited by indomethacin, high sodium intake or absent kidney function. This supports a possible early hemodynamic contribution, not a guaranteed explanation for every rapid improvement in pulmonary edema. [30]
After rapid correction of chronic hypercapnia, previously retained bicarbonate can persist and produce post-hypercapnic metabolic alkalosis. Concurrent loop-related chloride and potassium depletion can sustain it. Interpret the current pH, PaCO2 and bicarbonate together and correct the contributing deficits according to circulation and kidney function. [29][1]
A prespecified ADVOR analysis found more creatinine rises during acetazolamide treatment, although the between-group creatinine difference was not sustained at three months. Assess renal results alongside decongestion and clinical stability; this is not permission to disregard progressive AKI or hypotension. [31]
A traditional explanation for thiazide antidiuresis in DI is mild sodium and volume depletion with increased proximal sodium-water reclamation, reducing downstream delivery. Treat this as a useful partial model rather than a settled sole mechanism. Experimental antidiuresis has occurred without a corresponding measured decrease in distal delivery. [32]
Match the exception to the patient
Severe hypercalcemia requires treatment of the cause and hydration tailored to circulation and cardiac function. A loop drug is reserved for resulting or concurrent fluid overload, not routinely paired with saline to force calcium excretion. For adults with malignancy-associated calcium above 14 mg/dL, the Endocrine Society conditionally suggests initial calcitonin with an IV bisphosphonate or denosumab, based on very low certainty evidence. Limit calcitonin to 48 to 72 hours because tachyphylaxis limits sustained benefit. [27] A calcium transport mechanism alone is not a treatment guideline. [22]
A reported sulfonamide antibiotic allergy does not automatically prohibit furosemide or a thiazide. Immunologic cross-reactivity with nonantimicrobial sulfonamides is unlikely. Clarify the culprit and reaction, especially a severe cutaneous reaction or a prior reaction to the proposed diuretic itself. Ethacrynic acid is a non-sulfonamide loop option when clinically appropriate, but still carries ototoxic and electrolyte risks. [13]
Tolvaptan blocks V2 receptors; conivaptan blocks V1a and V2 receptors. They increase excretion of relatively electrolyte-free water. SAMSCA labeling requires hospital initiation or reinitiation of tolvaptan for hyponatremia, limits that use to thirty days, and advises avoiding underlying liver disease including cirrhosis. It is inappropriate for hypovolemic hyponatremia, inability to respond to thirst, anuria, or urgent treatment of serious neurological symptoms. Such symptoms require a monitored hypertonic saline strategy. Rapid sodium correction remains dangerous with any aquaretic. [4][21]
Before continuing a regimen, name the intended outcome and its monitoring signal. Congestion should improve without unacceptable loss of perfusion. A blood pressure drug needs blood pressure and laboratory follow-up. Potassium-sparing therapy requires a potassium plan. A new sodium abnormality, gout attack, hearing symptom, or acid-base disturbance should prompt a mechanism-based medication review rather than an automatic additional prescription.
Try it here · Checkpoint 3 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 7
Show answer and explanations for case 7
A. Substitute ethacrynic acid for furosemide while continuing gentamicin therapy (Why this does not fit)
Ethacrynic acid also carries ototoxicity risk and does not resolve the interacting exposure.
B. Continue both drugs unchanged and arrange formal hearing review after discharge (Why this does not fit)
New tinnitus during this high-risk combination warrants prompt medication and hearing assessment.
C. Deliver the next furosemide dose more rapidly (Why this does not fit)
Rapid administration is a risk factor, not a way to protect hearing.
D. Review ototoxic exposures and furosemide delivery, and assess hearing now (Best answer)
Renal impairment, rapid administration, and an aminoglycoside all increase loop-associated hearing injury risk.
Takeaway: New hearing symptoms require a targeted medication and administration review.
A. Direct carbonic anhydrase inhibition causing urinary bicarbonate loss and acidosis (Why this does not fit)
That mechanism causes bicarbonate loss and metabolic acidosis, whereas this patient developed alkalosis after a loop drug.
B. More distal sodium delivery increases potassium and hydrogen secretion (Best answer)
Loop blockade delivers more sodium downstream. Distal sodium absorption, flow, and aldosterone favor potassium and acid loss in this congested patient.
C. Collecting duct ENaC inhibition that reduces potassium secretion (Why this does not fit)
ENaC inhibition reduces the electrical drive for potassium secretion and tends toward potassium retention, opposite to the measured potassium fall.
D. V2 receptor blockade causing electrolyte-free water excretion (Why this does not fit)
Furosemide targets NKCC2. Aquaresis alone does not explain the characteristic potassium-depleted alkalosis after loop natriuresis.
Takeaway: Predict distal consequences of an upstream sodium transport block.
A. Direct blockade of collecting duct water channels (Why this does not fit)
Reduced collecting duct water permeability would promote water excretion, opposing the falling sodium concentration.
B. Complete abolition of the medullary concentrating gradient (Why this does not fit)
That is closer to a loop effect and would limit concentration; the highly concentrated urine here shows ongoing antidiuresis.
C. Impaired salt absorption in a cortical diluting segment (Best answer)
NCC inhibition limits dilute urine formation while water intake and antidiuresis continue, allowing sodium concentration to fall.
D. Reduced dietary solute intake as the sole new cause (Why this does not fit)
Low solute can limit water excretion, but the new NCC inhibitor and concentrated urine identify impaired dilution with antidiuresis as the specific drug-related mechanism.
Takeaway: Thiazides can cause severe hyponatremia by limiting dilution.
A. Use calcitonin alone as the sustained calcium-lowering treatment (Why this does not fit)
Calcitonin is short acting and limited by tachyphylaxis; an antiresorptive addresses sustained control.
B. Add scheduled furosemide to increase urinary calcium loss (Why this does not fit)
Routine loop treatment for calciuresis can worsen depletion; reserve a loop for clinically important overload.
C. Use an antiresorptive and consider calcitonin for the first 48 to 72 hours (Best answer)
For adults with malignancy-associated calcium above 14 mg/dL, the guideline conditionally suggests this combination on very low certainty evidence; monitor response and volume.
D. Defer antiresorptive treatment until hydration alone has failed for several days (Why this does not fit)
Severe malignancy-associated hypercalcemia warrants active calcium-directed therapy while hydration is individualized.
Takeaway: A calcium-excreting mechanism does not justify routine loop treatment of hypercalcemia.
A. Drug-induced lupus causing inflammatory arthritis (Why this does not fit)
Chlorthalidone-associated urate increase fits an acute first-metatarsophalangeal attack in a patient with gout better than an unestablished lupus syndrome.
B. An increase in calcium-phosphate precipitation within the joint (Why this does not fit)
Acute podagra in a patient with gout is best explained by urate; this is not the characteristic thiazide mechanism.
C. Increased serum urate associated with thiazide-like therapy (Best answer)
Hyperuricemia and gout are recognized adverse effects and fit the timing and joint syndrome.
D. Hypomagnesemia causing calcium pyrophosphate arthritis (Why this does not fit)
Magnesium depletion can be associated with CPP crystal disease, but prior gout and a new urate-raising drug make hyperuricemia the best link to podagra here.
Takeaway: Connect a new symptom to a specific metabolic adverse effect without ignoring alternative diagnoses.
A. Metabolic alkalosis after rapid reduction of chronic hypercapnia (Best answer)
Retained bicarbonate persists after PaCO2 falls; chloride and potassium depletion help maintain the alkalosis. The given values satisfy the Henderson-Hasselbalch relationship to rounding.
B. Normal-gap metabolic acidosis with respiratory compensation (Why this does not fit)
Bicarbonate is increased and pH is alkalemic, opposite to this primary metabolic disorder.
C. Acute respiratory alkalosis with appropriate buffering (Why this does not fit)
A loop impairs the medullary concentrating mechanism and is not the usual class selected for this antidiuretic purpose.
B. Osmotic diuretic (Why this does not fit)
An osmotic diuretic increases solute-associated water excretion rather than serving as routine treatment to reduce this polyuria.
C. Carbonic anhydrase inhibitor (Why this does not fit)
This increases bicarbonate loss and is not the standard class used for the thiazide antidiuretic effect asked about.
D. Thiazide diuretic (Best answer)
Selected thiazide therapy can paradoxically reduce urine volume in nephrogenic DI. It still requires monitoring of sodium, potassium, kidney function and circulation.
Takeaway: A diuretic can have a different net water effect when used for nephrogenic diabetes insipidus.
